User menu

Accès à distance ? S'identifier sur le proxy UCLouvain | Saint-Louis

Determination of tumour hypoxia with the PET tracer [18F]EF3: improvement of the tumour-to-background ratio in a mouse tumour model.

  1. Bush RS, Jenkin RD, Allt WE, Beale FA, Bean H, Dembo AJ, et al. Definitive evidence for hypoxic cells influencing cure in cancer therapy. Br J Cancer Suppl 1978;37:302–6.
  2. Hockel M, Schlenger K, Aral B, Mitze M, Schaffer U, Vaupel P. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 1996;56:4509–15.
  3. Fyles AW, Milosevic M, Wong R, Kavanagh MC, Pintilie M, Sun A, et al. Oxygenation predicts radiation response and survival in patients with cervix cancer. Radiother Oncol 1998;48:149–56.
  4. Hockel M, Knoop C, Schlenger K, Vorndran B, Baussmann E, Mitze M, et al. Intratumoral pO2 predicts survival in advanced cancer of the uterine cervix. Radiother Oncol 1993;26:45–50.
  5. Nordsmark Marianne, Overgaard Marie, Overgaard Jens, Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck, 10.1016/s0167-8140(96)91811-3
  6. Hodgkiss RJ. Use of 2-nitroimidazoles as bioreductive markers for tumour hypoxia. Anticancer Drug Des 1998;13:687–702.
  7. Sorensen M, Horsman MR, Cumming P, Munk OL, Keiding S. Effect of intratumoral heterogeneity in oxygenation status on FMISO PET, autoradiography, and electrode pO2 measurements in murine tumors. Int J Radiat Oncol Biol Phys 2005;62:854–61.
  8. Josse O, Labar D, Georges B, Gregoire V, Marchand-Brynaert J. Synthesis of [18F]-labeled EF3 [2-(2-nitroimidazol-1-yl)-N-(3,3,3-trifluoropropyl)-acetamide], a marker for PET detection of hypoxia. Bioorg Med Chem 2001;9:665–75.
  9. Yang D J, Wallace S, Cherif A, Li C, Gretzer M B, Kim E E, Podoloff D A, Development of F-18-labeled fluoroerythronitroimidazole as a PET agent for imaging tumor hypoxia., 10.1148/radiology.194.3.7862981
  10. Evans SM, Kachur AV, Shiue CY, Hustinx R, Jenkins WT, Shive GG, et al. Noninvasive detection of tumor hypoxia using the 2-nitroimidazole [18F]EF1. J Nucl Med 2000;41:327–36.
  11. Ziemer LS, Evans SM, Kachur AV, Shuman AL, Cardi CA, Jenkins WT, et al. Noninvasive imaging of tumor hypoxia in rats using the 2-nitroimidazole [18F]EF5. Eur J Nucl Med Mol Imaging 2003;30:259–66.
  12. Mahy P, De Bast M, Leveque PH, Gillart J, Labar D, Marchand J, et al. Preclinical validation of the hypoxia tracer 2-(2-nitroimidazol-1-yl)-N-(3,3,3-[18F]trifluoropropyl)acetamide, [18F]EF3. Eur J Nucl Med Mol Imaging 2004;31:1263–72.
  13. Mahy P, De Bast M, Gillart J, Labar D, Gregoire V. Detection of tumour hypoxia: comparison between EF5 adducts and [18F]EF3 uptake on an individual mouse tumour basis. Eur J Nucl Med Mol Imaging 2006;33:553–6.
  14. Akel G, Canal P, Soula G. Renal elimination of the hypoxic cell radiosensitizer misonidazole in Wistar rats: influence of some drugs on its excretion. Eur J Drug Metab Pharmacokinet 1985;10:181–7.
  15. de Jong M, Barone R, Krenning E, Bernard B, Melis M, Visser T, et al. Megalin is essential for renal proximal tubule reabsorption of 111In-DTPA-octreotide. J Nucl Med 2005;46:1696–700.
  16. Barone R, Pauwels S, De Camps J, Krenning EP, Kvols LK, Smith MC, et al. Metabolic effects of amino acid solutions infused for renal protection during therapy with radiolabelled somatostatin analogues. Nephrol Dial Transplant 2004;19:2275–81.
  17. Schuetz EG. Induction of cytochromes P450. Curr Drug Metab 2001;2:139–47.
  18. Milas L, Hunter N, Mason K, Withers HR. Immunological resistance to pulmonary metastases in C3Hf-Bu mice bearing syngeneic fibrosarcoma of different sizes. Cancer Res 1974;34:61–71.
  19. Surti S, Karp JS, Perkins AE, Cardi CA, Daube-Witherspoon ME, Kuhn A, et al. Imaging performance of A-PET: a small animal PET camera. IEEE Transactions on Medical Imaging 2005;24:844–52.
  20. Workman P, Brown JM. Structure-pharmacokinetic relationships for misonidazole analogues in mice. Cancer Chemother Pharmacol 1981;6:39–49.
  21. Yang XP, Liu YH, Rhaleb NE, Kurihara N, Kim HE, Carretero OA. Echocardiographic assessment of cardiac function in conscious and anesthetized mice. Am J Physiol 1999;277:H1967–74.
  22. Stypinski D, Wiebe LI, Tam YK, Mercer JR, McEwan AJ. Effects of methoxyflurane anesthesia on the pharmacokinetics of 125I-IAZA in Sprague-Dawley rats. Nucl Med Biol 1999;26:959–65.
Bibliographic reference Christian, Nicolas ; Bol, Anne ; De Bast, Marc ; Labar, Daniel ; Lee, John Aldo ; et. al. Determination of tumour hypoxia with the PET tracer [18F]EF3: improvement of the tumour-to-background ratio in a mouse tumour model.. In: European journal of nuclear medicine and molecular imaging, Vol. 34, no. 9, p. 1348-54 (2007)
Permanent URL